Limits...
Loss of gastric gland mucin-specific O-glycan is associated with progression of differentiated-type adenocarcinoma of the stomach.

Shiratsu K, Higuchi K, Nakayama J - Cancer Sci. (2013)

Bottom Line: Loss of αGlcNAc was also significantly associated with poorer patient prognosis in MUC6-positive differentiated-type adenocarcinoma.In undifferentiated-type adenocarcinoma, we observed no significant correlation between mucin phenotypic marker expression, including MUC6, and any clinicopathologic variable.These results together indicate that loss of αGlcNAc in MUC6-positive cancer cells is associated with progression and poor prognosis in differentiated, but not undifferentiated, types of gastric adenocarcinoma.

View Article: PubMed Central - PubMed

Affiliation: Department of Molecular Pathology, Shinshu University Graduate School of Medicine, Matsumoto, Japan; Department of Gastroenterology, Aizawa Hospital, Matsumoto, Japan.

Show MeSH

Related in: MedlinePlus

Cancer-specific survival in patients with MUC6-positive gastric cancer based on α1,4-linked N-acetylglucosamine (αGlcNAc) expression. (a) In MUC6-positive differentiated-type adenocarcinoma, patients with αGlcNAc-negative tumors had a significantly poorer outcome than patients with αGlcNAc-positive tumors (P = 0.048). (b) In MUC6-positive undifferentiated-type adenocarcinoma, there was no significant difference between patient survival rate and the presence or absence of αGlcNAc in tumors (P = 0.549).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4317868&req=5

fig05: Cancer-specific survival in patients with MUC6-positive gastric cancer based on α1,4-linked N-acetylglucosamine (αGlcNAc) expression. (a) In MUC6-positive differentiated-type adenocarcinoma, patients with αGlcNAc-negative tumors had a significantly poorer outcome than patients with αGlcNAc-positive tumors (P = 0.048). (b) In MUC6-positive undifferentiated-type adenocarcinoma, there was no significant difference between patient survival rate and the presence or absence of αGlcNAc in tumors (P = 0.549).

Mentions: Of samples from 54 patients with differentiated-type gastric adenocarcinoma showing MUC6-positivity in tumor cells, 33 (61.1%) lacked αGlcNAc expression (Table3). Notably, αGlcNAc expression was inversely correlated with depth of invasion, stage, and venous invasion. More importantly, analysis of 5-year cancer-specific survival rates of patients with MUC6-positive cancer cells revealed that individuals with αGlcNAc-negative tumors had a significantly poorer outcome than those showing αGlcNAc-positive tumors (P = 0.048) (Fig.5a).


Loss of gastric gland mucin-specific O-glycan is associated with progression of differentiated-type adenocarcinoma of the stomach.

Shiratsu K, Higuchi K, Nakayama J - Cancer Sci. (2013)

Cancer-specific survival in patients with MUC6-positive gastric cancer based on α1,4-linked N-acetylglucosamine (αGlcNAc) expression. (a) In MUC6-positive differentiated-type adenocarcinoma, patients with αGlcNAc-negative tumors had a significantly poorer outcome than patients with αGlcNAc-positive tumors (P = 0.048). (b) In MUC6-positive undifferentiated-type adenocarcinoma, there was no significant difference between patient survival rate and the presence or absence of αGlcNAc in tumors (P = 0.549).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4317868&req=5

fig05: Cancer-specific survival in patients with MUC6-positive gastric cancer based on α1,4-linked N-acetylglucosamine (αGlcNAc) expression. (a) In MUC6-positive differentiated-type adenocarcinoma, patients with αGlcNAc-negative tumors had a significantly poorer outcome than patients with αGlcNAc-positive tumors (P = 0.048). (b) In MUC6-positive undifferentiated-type adenocarcinoma, there was no significant difference between patient survival rate and the presence or absence of αGlcNAc in tumors (P = 0.549).
Mentions: Of samples from 54 patients with differentiated-type gastric adenocarcinoma showing MUC6-positivity in tumor cells, 33 (61.1%) lacked αGlcNAc expression (Table3). Notably, αGlcNAc expression was inversely correlated with depth of invasion, stage, and venous invasion. More importantly, analysis of 5-year cancer-specific survival rates of patients with MUC6-positive cancer cells revealed that individuals with αGlcNAc-negative tumors had a significantly poorer outcome than those showing αGlcNAc-positive tumors (P = 0.048) (Fig.5a).

Bottom Line: Loss of αGlcNAc was also significantly associated with poorer patient prognosis in MUC6-positive differentiated-type adenocarcinoma.In undifferentiated-type adenocarcinoma, we observed no significant correlation between mucin phenotypic marker expression, including MUC6, and any clinicopathologic variable.These results together indicate that loss of αGlcNAc in MUC6-positive cancer cells is associated with progression and poor prognosis in differentiated, but not undifferentiated, types of gastric adenocarcinoma.

View Article: PubMed Central - PubMed

Affiliation: Department of Molecular Pathology, Shinshu University Graduate School of Medicine, Matsumoto, Japan; Department of Gastroenterology, Aizawa Hospital, Matsumoto, Japan.

Show MeSH
Related in: MedlinePlus